9IB Stock Chart & Stats
€4.48
-€0.15(-3.23%)
At close: 4:00 PM EST
€4.48
-€0.15(-3.23%)
Day’s Range― - ―
52-Week Range€3.91 - €6.81
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€76.09M
Enterprise Value€834.40
Total Cash (Recent Filing)€108.60M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Nov 13, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.09
Shares Outstanding13,018,137
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)6.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.61
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero debt removes contractual interest obligations and reduces refinancing pressure, giving management more flexibility while clinical development continues. This does not solve funding needs, but it is a durable balance-sheet advantage versus a similarly pre-revenue biotech carrying debt.
Moderating Cash BurnAlthough cash generation remains negative, the smaller burn from 2024 through the TTM period indicates spending moderation. If maintained, this could improve capital efficiency and reduce the pace at which development must be funded externally, though the business is not yet self-funding.
Focused Microbiome StrategyIBT has a clearly defined therapeutic focus centered on microbiome-based medicines for vulnerable infant populations. Concentrating research on a specific clinical need and lead program targeting NEC can support focused development and differentiation if clinical and regulatory outcomes are successful.
Bears Say
Pre-revenue Operating ModelThe absence of revenue means IBT currently has no demonstrated commercial engine to absorb research and development costs. Substantial operating losses therefore remain dependent on future clinical success, regulatory approval and eventual commercialization or partnering.
Persistent Cash DependencePersistent negative operating and free cash flow indicate that ongoing development consumes capital rather than generating it. Until products or partnerships produce cash inflows, IBT remains dependent on external funding, which can constrain strategic flexibility and create financing risk.
Declining Equity BaseThe sharp decline in equity reflects accumulated losses and cash consumption, weakening the financial cushion available to support development. Negative returns on equity reinforce that capital has not yet produced sustainable value, increasing reliance on future clinical progress to reverse erosion.
Infant Bacterial Therapeutics AB News
9IB FAQ
What was Infant Bacterial Therapeutics AB’s price range in the past 12 months?
Infant Bacterial Therapeutics AB lowest stock price was €3.91 and its highest was €6.81 in the past 12 months.
What is Infant Bacterial Therapeutics AB’s market cap?
Infant Bacterial Therapeutics AB’s market cap is €76.09M.
When is Infant Bacterial Therapeutics AB’s upcoming earnings report date?
Infant Bacterial Therapeutics AB’s upcoming earnings report date is Nov 13, 2026 which is in 59 days.
How were Infant Bacterial Therapeutics AB’s earnings last quarter?
Infant Bacterial Therapeutics AB released its earnings results on Aug 26, 2026. The company reported -€0.196 earnings per share for the quarter, missing the consensus estimate of -€0.139 by -€0.058.
Is Infant Bacterial Therapeutics AB overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics AB’s price is currently Overvalued.
Does Infant Bacterial Therapeutics AB pay dividends?
Infant Bacterial Therapeutics AB does not currently pay dividends.
What is Infant Bacterial Therapeutics AB’s EPS estimate?
Infant Bacterial Therapeutics AB’s EPS estimate is -0.24.
How many shares outstanding does Infant Bacterial Therapeutics AB have?
Infant Bacterial Therapeutics AB has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics AB’s price movement after its last earnings report?
Infant Bacterial Therapeutics AB reported an EPS of -€0.196 in its last earnings report, missing expectations of -€0.139. Following the earnings report the stock price went up 2.838%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics AB?
Currently, no hedge funds are holding shares in DE:9IB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Xbrane Biopharma AB
―
Intervacc AB
―
ExpreS2ion Biotech Holding AB
―